Form 10 Explorer
10-Q
Quarterly Report
AIM IMMUNOTECH INC.

AIM

NYSEAMER

CIK: 946644

File #: 001-27072

Period End: Mar 31, 2025

Fiscal Year: 2025

View on EDGAR
Balance Sheet
34 line items · 2 periods
XBRL
ItemMar 31, 2025Dec 31, 2024
ASSETS
Current assets:
Cash and Cash Equivalents
898,0001,701,000
Cash and Cash Equivalents
1,349,0002,276,000
Fair Value, Inputs, Level 1
1,349,0002,276,000
Other Non-Operating Current Assets
19,000
Other Non-Operating Current Assets
318,000199,000
Total current assets
2,584,0004,176,000
Property, Plant and Equipment
98,000108,000
Operating Lease Right-of-Use Asset
554,000618,000
Intangible Assets
2,267,0002,594,000
Patents
2,173,0002,495,000
Trademarks
94,00099,000
Other Non-Operating Non-Current Assets
745,0001,112,000
Total assets
6,248,0008,608,000
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts Payable
6,944,0006,383,000
Other Current Liabilities
639,000606,000
Operating Lease Liability, Current
234,000239,000
Short-Term Debt
1,950,0002,307,000
Total current liabilities
9,767,0009,535,000
Long-term liabilities:
Operating Lease Liability, Non-Current
338,000395,000
Total liabilities
10,105,0009,930,000
Stockholders’ deficit:
Total Stockholders' Equity
72,00066,000
Total Stockholders' Equity
426,604,000425,440,000
Total Stockholders' Equity
(430,533,000)(426,828,000)
Total stockholders’ deficit
(3,857,000)(1,322,000)
Common Stock
72,00066,000
Additional Paid-in Capital
426,604,000425,440,000
Retained Earnings
(430,533,000)(426,828,000)
Total liabilities and stockholders’ deficit
6,248,0008,608,000